Clinical Insights on Treating Metastatic Triple-Negative Breast Cancer

Opinion
Video

Ruth M. O’Regan, MD, and Anna Weiss, MD, discuss treatment paradigms for patients with metastatic triple-negative breast cancer and the role of surgery.

Recent Videos
Findings from David Rimm, MD, PhD, suggest that there may be an inverse relationship between HER2 and TROP2 expression among patients with breast cancer.
Tissue samples collected from patients with breast cancer during treatment may help explore therapy selection and predict toxicities.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Related Content
Sessions from SABCS 2025 detailed potential advances across different immunotherapy, radiation, and surgical modalities in breast cancer care.

SABCS 2025: The Top 5 Takeaways for Breast Cancer Research

Russ Conroy
December 18th 2025
Article

Sessions from SABCS 2025 detailed potential advances across different immunotherapy, radiation, and surgical modalities in breast cancer care.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Imlunestrant Combo Will Not Be Pursued for FDA Approval in Breast Cancer

Imlunestrant Combo Will Not Be Pursued for FDA Approval in Breast Cancer

Ariana Pelosci
December 17th 2025
Article

A label for imlunestrant/abemaciclib in ER+/HER2– advanced breast cancer with ESR1 mutations will be sought.

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Atezolizumab/NAT May Impact Fertility in TNBC

Atezolizumab/NAT May Impact Fertility in TNBC

Silas Inman
December 16th 2025
Article

Atezolizumab plus neoadjuvant therapy was found to increase chemotherapy-induced ovarian failure among patients with TNBC.

Data from SERENA-6 showed delayed disease progression and deterioration in QOL among patients who switched to camizestrant plus CDK4/6 inhibition.

Switching to Camizestrant Combo Improves PFS in HR+/HER2– Breast Cancer

Caroline Seymour
December 15th 2025
Article

Data from SERENA-6 showed delayed disease progression and deterioration in QOL among patients who switched to camizestrant plus CDK4/6 inhibition.